Now showing items 1-9 of 9

    • CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. 

      Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; Nutting, CM; Newbold, KL; Bhide, S; Harrington, KJ (2016-09)
      Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ...
    • Clinical development of new drug-radiotherapy combinations. 

      Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)
      In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...
    • Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. 

      Nuta, O; Somaiah, N; Boyle, S; Chua, MLK; Gothard, L; Yarnold, J; Rothkamm, K; Herskind, C (2016-05)
      Late normal tissue toxicity varies widely between patients and limits breast radiotherapy dose. Here we aimed to determine its relationship to DNA damage responses of fibroblast cultures from individual patients. Thirty-five ...
    • Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. 

      Andreassen, CN; Rosenstein, BS; Kerns, SL; Ostrer, H; De Ruysscher, D; Cesaretti, JA; Barnett, GC; Dunning, AM; Dorling, L; West, CML; Burnet, NG; Elliott, R; Coles, C; Hall, E; Fachal, L; Vega, A; Gómez-Caamaño, A; Talbot, CJ; Symonds, RP; De Ruyck, K; Thierens, H; Ost, P; Chang-Claude, J; Seibold, P; Popanda, O; Overgaard, M; Dearnaley, D; Sydes, MR; Azria, D; Koch, CA; Parliament, M; Blackshaw, M; Sia, M; Fuentes-Raspall, MJ; Ramon Y Cajal, T; Barnadas, A; Vesprini, D; Gutiérrez-Enríquez, S; Mollà, M; Díez, O; Yarnold, JR; Overgaard, J; Bentzen, SM; Alsner, J; International Radiogenomics Consortium (RgC) (2016-12)
      PURPOSE:Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a ...
    • Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. 

      Kerns, SL; Dorling, L; Fachal, L; Bentzen, S; Pharoah, PDP; Barnes, DR; Gómez-Caamaño, A; Carballo, AM; Dearnaley, DP; Peleteiro, P; Gulliford, SL; Hall, E; Michailidou, K; Carracedo, Á; Sia, M; Stock, R; Stone, NN; Sydes, MR; Tyrer, JP; Ahmed, S; Parliament, M; Ostrer, H; Rosenstein, BS; Vega, A; Burnet, NG; Dunning, AM; Barnett, GC; West, CML; Radiogenomics Consortium (2016-08)
      Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. ...
    • Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. 

      Panek, R; Welsh, L; Baker, LCJ; Schmidt, MA; Wong, KH; Riddell, AM; Koh, D-M; Dunlop, A; Mcquaid, D; d'Arcy, JA; Bhide, SA; Harrington, KJ; Nutting, CM; Hopkinson, G; Richardson, C; Box, C; Eccles, SA; Leach, MO; Robinson, SP; Newbold, KL (2017-08)
      Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of cycling hypoxia, and the assessment of its extent and spatial distribution, in head and neck squamous cell carcinoma (HNSCC) xenografts and ...
    • p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. 

      Yogev, O; Barker, K; Sikka, A; Almeida, GS; Hallsworth, A; Smith, LM; Jamin, Y; Ruddle, R; Koers, A; Webber, HT; Raynaud, FI; Popov, S; Jones, C; Petrie, K; Robinson, SP; Keun, HC; Chesler, L (2016-05)
      Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare ...
    • Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy. 

      Agliano, A; Balarajah, G; Ciobota, DM; Sidhu, J; Clarke, PA; Jones, C; Workman, P; Leach, MO; Al-Saffar, NMS (2017-07)
      Poor outcome for patients with glioblastomas is often associated with radioresistance. PI3K/mTOR pathway deregulation has been correlated with radioresistance; therefore, PI3K/mTOR inhibition could render tumors radiosensitive. ...
    • Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. 

      Dillon, MT; Barker, HE; Pedersen, M; Hafsi, H; Bhide, SA; Newbold, KL; Nutting, CM; McLaughlin, M; Harrington, KJ (2017-01)
      AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory activity of this ATRi in a panel of human cancer cell lines. We demonstrated radiosensitization by ...